NiKang Therapeutics Inc., a clinical-stage biotech company focused on developing small molecule oncology medicines to help patients with unmet medical needs and Hansoh Pharmaceutical Group Company Limited, a China and US-based leading biopharmaceutical company, announced a collaboration and license agreement for the development and commercialization of NKT2152, for the treatment of cancer in Mainland China, Hong Kong, Macau, and Taiwan.
“Hansoh is a leader in the development and commercialization of small molecules for the treatment of cancer in China. We are thrilled to collaborate with them to strategically advance NKT2152 and expand its reach as a potential treatment for multiple tumor types,” said Zhenhai Gao, Ph.D., co-founder, and CEO of NiKang. “By combining NiKang’s precision oncology expertise with Hansoh’s proven development and commercialization capabilities in Greater China, we believe that we will be able to accelerate global development of NKT2152 and bring it as a potential novel cancer treatment to China patients sooner.”
NiKang is based near Wilmington.
Under the terms of the agreement, NiKang will receive an upfront cash payment of $15 million and will be eligible to receive up to $203 million in potential development, regulatory and sales-based milestone payments, and tiered royalties. Hansoh will be responsible for all the development costs for NKT2152 in Greater China and will receive the exclusive rights to develop and commercialize NKT2152 in the region.
NKT2152 is a small molecule that inhibits HIF2α. It is currently in a phase 1/2 dose escalation and expansion trial. This trial is designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity in patients with a form of advanced kidney cancer.
About NiKang Therapeutics
NiKang Therapeutics is a clinical-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Our target selection is driven by deep insights into disease biology and molecular pathways. Our discovery approach is informed by target structure biology and capitalizes on structure-based drug design. The successful implementation of our strategy enables us to rapidly and efficiently discover and advance proprietary drugs. For more information, visit www.nikangtx.com.
Hansoh Pharma is one of the largest biopharmaceutical companies in China and has 12,150 employees in China and the United States.